
Ainos ( ($AIMD) ) has provided an announcement. On November 12, 2026, Ainos entered into an agreement with ASE Technology Holding Co., Ltd. to sell 5,000 AI Nose systems for
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| AIMD | Ainos | 1.23 | -1.18 | -48.88% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.23 | -48.88% |

Ainos ( ($AIMD) ) has provided an announcement. On November 12, 2026, Ainos entered into an agreement with ASE Technology Holding Co., Ltd. to sell 5,000 AI Nose systems for

Eddy Tsai, Chairman, President and Chief Executive Officer, commented: “Our third-quarter results show progress in translating commercial agreements into revenue. Revenue reached $642,889, up 29,567% year over year, driven by

Ainos (AIMD) has signed a $9 million purchase agreement with ASE Technology Holding (ASX) for 5,000 additional AI Nose systems. The agreement represents the largest single purchase order by value

Ainos (AIMD) announced that its AI Nose platform has accumulated more than 3 billion real-world chemical data points, surpassing three times the 1 billion milestone announced in September. The rapid

Ainos ( ($AIMD) ) has shared an announcement. On October 14, 2026, Ainos, Inc. adopted amended Corporate Governance Policies that formalize a classified board structure divided into three staggered classes

Ainos (AIMD) has completed the required data delivery and technology transfer under its VELDONA license agreement, triggering a $600,000 initial license payment. The licensing partner confirmed completion in writing on

Ainos (AIMD) has completed delivery of all 1,400 AI Nose systems to ASE Technology Holding under the announced $2.1M, three-year agreement. The completed delivery marks a major commercial milestone for

An announcement from Ainos ( ($AIMD) ) is now available. On September 24, 2026, Ainos granted Taiwan-based BioPhoenix a global, exclusive and sublicensable license to develop and commercialize its VELDONA

Ainos (AIMD) detailed the financial and strategic benefits of the VELDONA License Agreement announced on September 24. Ainos expects to complete the agreed contractual delivery shortly, with an initial license

Ainos (AIMD) entered into a VELDONA License Agreement with BioPhoenix, establishing a collaboration framework with a potential aggregate value of $10M. The framework comprises an initial license fee, conditional consideration
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 5, 2027TBA | $9.94M | ― | ― | -0.00 | -0.63 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.